Skip to main content

Table 1 Clinical parameters before and after administration of dapagliflozin or sitagliptin

From: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

  Dapagliflozin (n = 40) Sitagliptin (n = 40) p valueb
Pre treatment Post treatment % change p valuea Pre treatment Post treatment % change p valuea
BW (kg) 78.4 ± 14.3 76.2 ± 1.8 −2.8 <0.001* 77.6 ± 11.6 77.7 ± 11.6 0.1 0.089 0.042*
SBP (mmHg) 130.7 ± 15.8 126.5 ± 12.7 −3.2 0.022* 133.2 ± 17.8 131.0 ± 13.3 −1.7 0.611 0.031*
DBP (mmHg) 86.9 ± 10.7 82.3 ± 16.0 −5.3 0.188 88.1 ± 9.5 84.4 ± 11.0 −4.2 0.024* 0.242
HR (bpm) 82.5 ± 10.4 81.6 ± 13.9 −1.1 0.300 81.5 ± 10.3 77.1 ± 10.8 −5.4 0.056 0.344
Hb (mg/dL) 14.4 ± 1.2 15.1 ± 1.4 4.9 <0.001* 14.2. ± 1.4 14.5 ± 1.5 2.1 0.088 <0.001*
Ht (%) 41.9 ± 3.5 44.5 ± 4.0 6.2 <0.001* 41.4 ± 4.3 41.9 ± 4.2 1.2 0.297 <0.001*
AST (IU/L) 34.5 ± 19.4 26.8 ± 12.8 −22.3 <0.001* 33.2 ± 9.8 35.4 ± 14.9 6.6 0.089 <0.001*
ALT (IU/L) 46.6 ± 37.0 33.5 ± 24.9 −28.1 <0.001* 42.8 ± 15.0 44.9 ± 18.4 4.9 0.202 <0.001*
γGTP (IU/L) 53.2 ± 43.0 42.3 ± 47.2 −20.5 0.109 50.9 ± 18.1 52.2 ± 22.0 2.6 0.729 0.107
BUN (mg/dL) 14.6 ± 4.3 16.8 ± 5.0 15.1 <0.001* 13.5 ± 4.5 15.3 ± 4.6 13.3 0.115 0.367
Cre (mg/dL) 0.72 ± 0.17 0.74 ± 0.23 2.8 0.173 0.77 ± 0.17 0.81 ± 0.18 5.2 0.110 0.757
eGFR (mL/min/1.73 m2) 86.2 ± 18.4 83.6 ± 23.2 −3.0 0.230 83.5 ± 22.7 79.2 ± 21.4 −5.1 0.003* 0.545
FPG (mg/dL) 145.8 ± 47.8 122.3 ± 24.9 −16.1 0.002* 144.9 ± 57.9 126.2 ± 43.9 −12.9 0.043* 0.673
HbA1c (%) 7.61 ± 1.15 6.86 ± 0.81 −9.9 <0.001* 7.55 ± 1.64 6.92 ± 1.20 −8.3 0.006* 0.378
C-peptide (ng/mL) 2.79 ± 1.39 2.40 ± 1.56 −14.0 0.018* 2.70 ± 1.25 2.78 ± 1.48 3.0 0.633 0.190
Adiponectin (ng/mL) 6.0 ± 3.4 7.6 ± 4.2 26.7 <0.001* 6.2 ± 5.3 6.2 ± 3.8 0 0.899 0.002*
  1. Data are expressed as mean ± standard deviation or percent changes after the treatment
  2. BW body weight, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, Hb hemoglobin, Ht hematocrit, AST aspartate aminotransferase, ALT alanine aminotransferase, γGTP γ-glutamyltranspeptidase, BUN blood urea nitrogen, Cre creatinine, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose
  3. ap values for the intragroup comparison (pre vs. post treatment values in dapagliflozin or sitagliptin group, * p < 0.05)
  4. bp values for intergroup comparison (dapagliflozin vs. sitagliptin group in the changes from pre to post treatment, * p < 0.05)